65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 84 — 0.166; 0.087 Liters — p=<0.001
Creutzfeldt-Jakob Disease
Primary: Primary Survival — 19; 13 participants — p=0.43
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 84 — 0.165; 0.091 Liters — p=<0.001
Alpha1-antitrypsin Deficiency · Healthy Volunteers
Primary: Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality…
Diagnostic Self Evaluation · Central Nervous System Diseases
Primary: MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" Evaluation — 1.06; 3.30; 1.62…
Surgical Adhesions
Primary: TAM2 — 108; 121 Degrees — p=0.8861
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Assay (Using Human Complement) (hSBA) Titers Equal to or Above the Cut-off Values — 102; 35; 15; 319 Subjects
Dentine Hypersensitivity
Primary: Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4 — -0.36; -0.43; -0.40; -0.45 Score on a scale — p=0.4553
Pain
Primary: Visual Analog Scale Pain Score — 6.5; 8.9; -2.4; 4.4 Visial Analog Pain Score (VAS)
Bacillus Anthracis (Anthrax)
Primary: Number of Participants With a Four-fold or Greater Increase From Baseline in Toxin Neutralization Antibody Assay (TNA) 50 Percent Neutralization Factor ( NF50 ) Antibody…
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: uNTX Response Rate at 43 Days — 14 percentage of participants
Breastfeeding
Primary: Program Feasibility- Feeding Outcome Collected — 287; 288; 314 participants
Clinical Use of PTH(1-84)
Primary: Number of Participants Who Discontinued Before 6 Months of Treatment — 181 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Incidence of Treatment Emergent Adverse Events (AEs) — 361; 331; 345; 321 Events/100 years of patient exposure
Depressive Disorder, Major
Primary: Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5% — 258; 80; 68; 65 participants